Additionally, despite its anti-tumor activity, GSK2656157 exerts a serious off-tumor side effects associated with the inhibition of PERK activity in the pancreas, which leads to impaired pancreatic function [185]. The gene discussed is EIF2AK3; the disease is neoplasm.